Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243003776> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4243003776 endingPage "123" @default.
- W4243003776 startingPage "117" @default.
- W4243003776 abstract "From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 to 67). Sixty-four (82 per cent) had diffuse large cell (Working Formulation category G) histology. The median LDH level was 453 u/l. Thirty-three (42·3 per cent) and 45 (57·7 per cent) had stage I/II and stage III/IV disease, respectively. Fifty-five of 78 (71 per cent) CEOP-treated patients achieved CR, and the projected DFS and OS were both 65 per cent. In an earlier cohort of patients (from 1985–1991) treated with second or third-generation chemotherapy regimens (m-BACOD, MACOP-B, ProMACE-CytaBOM), CR was achieved in 95/123 (77 per cent) patients and the projected DFS and OS were 62 per cent and 55 per cent. There was no significant difference in the clinical characteristics, CR rates (p=0·26), DFS (p=0·38) or OS (p=0·68) between patients who received CEOP or second hird-generation chemotherapy regimens. Of the patients treated with CEOP, 37·9 per cent, 28·8 per cent, 24·2 per cent and 9·1 per cent were in the age-adjusted International Index L, LI, HI and H risk groups, with CR rates of 82 per cent and 57 per cent in the L/LI and HI/H risk groups (p=0·03). Moreover, patients in the L, LI and HI/H risk groups had significantly different projected DFS (87 per cent, 62 per cent and 39 per cent, p=0·02) and OS (85 per cent, 80 per cent and 36 per cent, p=0·006). In conclusion, CEOP is an effective regimen and the age-adjusted International Index is valid for Chinese patients with aggressive NHL. Copyright © 1998 John Wiley & Sons, Ltd." @default.
- W4243003776 created "2022-05-12" @default.
- W4243003776 creator A5010037267 @default.
- W4243003776 creator A5027894786 @default.
- W4243003776 creator A5037326976 @default.
- W4243003776 creator A5068452064 @default.
- W4243003776 creator A5085953922 @default.
- W4243003776 date "1998-09-01" @default.
- W4243003776 modified "2023-10-14" @default.
- W4243003776 title "CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non‐Hodgkin's lymphoma" @default.
- W4243003776 doi "https://doi.org/10.1002/(sici)1099-1069(199809)16:3<117::aid-hon632>3.3.co;2-s" @default.
- W4243003776 hasPublicationYear "1998" @default.
- W4243003776 type Work @default.
- W4243003776 citedByCount "0" @default.
- W4243003776 crossrefType "journal-article" @default.
- W4243003776 hasAuthorship W4243003776A5010037267 @default.
- W4243003776 hasAuthorship W4243003776A5027894786 @default.
- W4243003776 hasAuthorship W4243003776A5037326976 @default.
- W4243003776 hasAuthorship W4243003776A5068452064 @default.
- W4243003776 hasAuthorship W4243003776A5085953922 @default.
- W4243003776 hasConcept C126322002 @default.
- W4243003776 hasConcept C141071460 @default.
- W4243003776 hasConcept C146357865 @default.
- W4243003776 hasConcept C151730666 @default.
- W4243003776 hasConcept C2776694085 @default.
- W4243003776 hasConcept C2776715498 @default.
- W4243003776 hasConcept C2776755627 @default.
- W4243003776 hasConcept C2778476033 @default.
- W4243003776 hasConcept C2778476748 @default.
- W4243003776 hasConcept C2779338263 @default.
- W4243003776 hasConcept C2779429289 @default.
- W4243003776 hasConcept C2779725641 @default.
- W4243003776 hasConcept C2780835546 @default.
- W4243003776 hasConcept C2781413609 @default.
- W4243003776 hasConcept C71924100 @default.
- W4243003776 hasConcept C86803240 @default.
- W4243003776 hasConcept C90924648 @default.
- W4243003776 hasConceptScore W4243003776C126322002 @default.
- W4243003776 hasConceptScore W4243003776C141071460 @default.
- W4243003776 hasConceptScore W4243003776C146357865 @default.
- W4243003776 hasConceptScore W4243003776C151730666 @default.
- W4243003776 hasConceptScore W4243003776C2776694085 @default.
- W4243003776 hasConceptScore W4243003776C2776715498 @default.
- W4243003776 hasConceptScore W4243003776C2776755627 @default.
- W4243003776 hasConceptScore W4243003776C2778476033 @default.
- W4243003776 hasConceptScore W4243003776C2778476748 @default.
- W4243003776 hasConceptScore W4243003776C2779338263 @default.
- W4243003776 hasConceptScore W4243003776C2779429289 @default.
- W4243003776 hasConceptScore W4243003776C2779725641 @default.
- W4243003776 hasConceptScore W4243003776C2780835546 @default.
- W4243003776 hasConceptScore W4243003776C2781413609 @default.
- W4243003776 hasConceptScore W4243003776C71924100 @default.
- W4243003776 hasConceptScore W4243003776C86803240 @default.
- W4243003776 hasConceptScore W4243003776C90924648 @default.
- W4243003776 hasIssue "3" @default.
- W4243003776 hasLocation W42430037761 @default.
- W4243003776 hasOpenAccess W4243003776 @default.
- W4243003776 hasPrimaryLocation W42430037761 @default.
- W4243003776 hasRelatedWork W2010862449 @default.
- W4243003776 hasRelatedWork W2088845007 @default.
- W4243003776 hasRelatedWork W2098671965 @default.
- W4243003776 hasRelatedWork W2158035792 @default.
- W4243003776 hasRelatedWork W2183352065 @default.
- W4243003776 hasRelatedWork W2368204729 @default.
- W4243003776 hasRelatedWork W2408113921 @default.
- W4243003776 hasRelatedWork W2426252699 @default.
- W4243003776 hasRelatedWork W247605849 @default.
- W4243003776 hasRelatedWork W2519696495 @default.
- W4243003776 hasVolume "16" @default.
- W4243003776 isParatext "false" @default.
- W4243003776 isRetracted "false" @default.
- W4243003776 workType "article" @default.